A Bright Future for Life Sciences in Australia
Posted: 10 October 2023 Tax Incentives can free up company finances to focus on business-critical activities. This paper will cover 4 key topics that we at Prime Financial believe are essential reading for key decision-makers for companies in…
New blood test could improve concussion diagnosis: study
Posted: 6 October 2023 A global blood test for concussion could be a step closer after a Monash University-led study discovered specific proteins or biomarkers that can help diagnose concussions relatively quickly and accurately. Once approved, a blood…
Update on Nasodine Trial and Forward Plans
Posted: 6 October 2023 Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) announces that the independent preliminary investigation into the Phase 3 trial results of Nasodine Nasal Spray (“Nasodine”) (refer ASX announcement 13 September 2023) has not revealed any systematic…
US FDA grants Orphan Drug Designation for CRO-67
Posted: 6 October 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) status to Noxopharm’s CRO-67 preclinical drug candidate, for the treatment of pancreatic cancer. The…
Xprecia Prime 4U approved for Patient Self-Testing in Europe
Posted: 6 October 2023 Universal Biosensors, Inc. (ASX: UBI) is pleased to announce it has received the approval required for the sale of “Xprecia Prime 4U” directly to patients for self-testing in Europe. The approval is in the…
Atmo Biosciences reaches 60 per cent recruitment target in dysmotility pivotal clinical study
Posted: 6 October 2023 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, has reached 60 per cent of its recruitment target for a pivotal clinical study…
Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer
Posted: 3 October 2023 Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates. In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and…
ANDHealth Achieves Top 10 Most Innovative Company Milestone
Posted: 3 October 2023 ANDHealth, Australia’s leading commercialisation organisation, has today been recognised as one of the top 10 most innovative companies in Australia in the Health Industries category in the Australian Financial Review’s BOSS annual Most Innovative…
Biobank aims to discover new treatments for children with genetic muscle diseases
Posted: 3 October 2023 An Australian first biobank will be established to improve and discover new treatments for children with genetic muscle diseases such as muscular dystrophy. The National Muscle Disease Bio-databank, co-led by Murdoch Children’s Research Institute, Monash…
MNHS researchers awarded $7.5million in NHMRC Centres of Research Excellence funding
Posted: 3 October 2023 The Federal Government has today announced $7.5 million in funding for three National Health and Medical Research Council (NHMRC) Centres of Research Excellence led by Monash Medicine Nursing and Allied Health researchers. The Centres of Research Excellence (CRE)…
Chance discovery shows promise in finding treatment for genetic disorder
Posted: 3 October 2023 Researchers have gained insight into how a toxic protein, known to trigger muscular dystrophy, could be ‘switched off’ – a pre-clinical discovery that could spearhead a treatment for the debilitating disease. Facioscapulohumeral muscular dystrophy…
Latest CRO-67 data shows success in reducing cancer growth
Posted: 3 October 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that further encouraging data from its Chroma™ platform has been presented at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer. The latest in…
